BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8785889)

  • 41. Twice- vs. thrice-weekly MPD PUVA in psoriasis: a randomized-controlled efficacy study.
    Valbuena MC; Hernández O; Rey M; Sánchez G; de Quintana LP
    Photodermatol Photoimmunol Photomed; 2007 Aug; 23(4):126-9. PubMed ID: 17598865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative efficacy of psoralen - UVA photochemotherapy versus narrow band UVB phototherapy in the treatment of psoriasis.
    Tahir R; Mujtaba G
    J Coll Physicians Surg Pak; 2004 Oct; 14(10):593-5. PubMed ID: 15456547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Photochemotherapy and dermatology: treatment with PUVA].
    Martineau L; Collins JP
    Union Med Can; 1983 May; 112(5):488-91. PubMed ID: 6879863
    [No Abstract]   [Full Text] [Related]  

  • 44. Bullous pemphigoid in a patient with psoriasis during the course of PUVA therapy: study by ELISA test.
    Barnadas MA; Gilaberte M; Pujol R; Agustí M; Gelpí C; Alomar A
    Int J Dermatol; 2006 Sep; 45(9):1089-92. PubMed ID: 16961518
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
    Feldman SR; Evans C; Russell MW
    J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of drugs and ultraviolet rays on the development of pemphigoid].
    Lutowiecka-Wranicz A; Sysa-Jedrzejowska A; Skwarczyńska-Banyś E
    Przegl Dermatol; 1980; 67(5):641-6. PubMed ID: 7005972
    [No Abstract]   [Full Text] [Related]  

  • 47. Long-term use of psoralens and ultraviolet A for psoriasis: evidence for efficacy and cost savings.
    Stern RS
    J Am Acad Dermatol; 1986 Mar; 14(3):520-6. PubMed ID: 3958270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The activity spectrum of psoralen photochemotherapy. Comparative treatment of psoriasis with 335 nm and 365 nm].
    Brücke J
    Wien Klin Wochenschr; 1989 Aug; 101(15):516-7. PubMed ID: 2773487
    [No Abstract]   [Full Text] [Related]  

  • 49. [Peroral PUVA treatment of psoriasis].
    Swanbeck G; Wennersten G
    Lakartidningen; 1979 Oct; 76(43):3762-5. PubMed ID: 529924
    [No Abstract]   [Full Text] [Related]  

  • 50. [Therapeutic effectiveness of psoralen-UV-A bath therapy in psoriasis].
    Rodríguez-Granados MT; Pereira-Rodríguez MJ; Vázquez-Vizoso FL
    Actas Dermosifiliogr; 2009 Apr; 100(3):212-21. PubMed ID: 19457307
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PUVA for psoriasis and other skin diseases.
    Drug Ther Bull; 1980 Jan; 18(1):1-3. PubMed ID: 7353478
    [No Abstract]   [Full Text] [Related]  

  • 52. Approval of PUVA for severe psoriasis.
    FDA Drug Bull; 1982 Aug; 12(2):13-4. PubMed ID: 7141170
    [No Abstract]   [Full Text] [Related]  

  • 53. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The Koebner phenomenon, a prognostic sign of PUVA therapy effectiveness in patients with psoriasis vulgaris--yes or no?].
    Matović L; Poljacki M; Duran V; Stojanović S; Subotić M
    Med Pregl; 1999; 52(11-12):437-40. PubMed ID: 10748764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis.
    Vongthongsri R; Konschitzky R; Seeber A; Treitl C; Hönigsmann H; Tanew A
    J Am Acad Dermatol; 2006 Oct; 55(4):627-31. PubMed ID: 17010742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Study under scanning electron microscopy of scales of PUVA treated psoriasis (authors's transl)].
    Barrière H; Litoux P
    Ann Dermatol Venereol; 1978 Oct; 105(10):801-4. PubMed ID: 747291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk assessment of PUVA and cyclosporine. Lessons from the past; challenges for the future.
    Stern RS
    Arch Dermatol; 1989 Apr; 125(4):545-7. PubMed ID: 2649014
    [No Abstract]   [Full Text] [Related]  

  • 58. [What are the objectives of moderate to severe psoriasis treatment?].
    Ortonne JP
    Ann Dermatol Venereol; 2008 Jul; 135 Suppl 5():S281-4. PubMed ID: 18721665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy.
    Yones SS; Palmer RA; Garibaldinos TT; Hawk JL
    Arch Dermatol; 2006 Jul; 142(7):836-42. PubMed ID: 16847198
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cutaneous manifestations of thrombocythaemia associated with myelofibrosis in a patient suffering from psoriasis and treated by PUVA (author's transl)].
    Bovet R; Cech P
    Dermatologica; 1980; 161(1):63-8. PubMed ID: 6893186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.